Regulatory B cells in rheumatoid arthritis Alterations in patients receiving anti-TNF therapy

Regulatory B cells in rheumatoid arthritis : Alterations in patients receiving anti-TNF therapy

Copyright © 2017 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 184(2017) vom: 15. Nov., Seite 63-69
1. Verfasser: Bankó, Zsuzsanna (VerfasserIn)
Weitere Verfasser: Pozsgay, Judit, Gáti, Tamás, Rojkovich, Bernadette, Ujfalussy, Ilona, Sármay, Gabriella
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't ACPA Anti-TNF therapy Il-10 Regulatory B cell Rheumatoid arthritis Antigens, CD Antigens, Differentiation, T-Lymphocyte Antirheumatic Agents mehr... Autoantibodies CD69 antigen IL10 protein, human IL2RA protein, human Interleukin-2 Receptor alpha Subunit Lectins, C-Type Peptides, Cyclic Tumor Necrosis Factor-alpha cyclic citrullinated peptide Interleukin-10 130068-27-8 Adalimumab FYS6T7F842 Etanercept OP401G7OJC Methotrexate YL5FZ2Y5U1
Beschreibung
Zusammenfassung:Copyright © 2017 Elsevier Inc. All rights reserved.
Cytokines, including tumor necrosis factor alpha (TNFα) are involved in Rheumatoid arthritis (RA) pathogenesis by augmenting autoimmunity, sustaining long term inflammation in the synovium, and promoting joint damage. Anti-TNF therapy is one of the most efficient and widely used therapies for RA, although its mechanism is not clarified yet. Earlier we demonstrated that RA patients have a reduced number of IL-10 producing regulatory B cells (B10 cells) as compared to healthy individuals and they are functionally impaired. Our aim was to study the influence of anti-TNF therapy on B10 cells in RA, to follow the alteration of B cell activation markers (CD25, CD69) and to monitor the level of citrullinated peptid-specific antibodies and the secreted IL-10 in patients' sera during the therapy. We have observed that at six month after starting the therapy the frequency of B10 cells remarkably increased, while the expression of the activation marker, CD69 decreased on B cells. In contrast, serum levels of IL-10 and anti-citrullinated peptide antibodies did not change post-treatment
CONCLUSION: The reduced activation state of B cells and the increasing number of regulatory B10. cells might contribute to the therapeutic efficacy of anti-TNF agents in RA
Beschreibung:Date Completed 16.11.2017
Date Revised 06.02.2018
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2017.05.012